Cutaneous Melanoma clinical trials

Explore recruiting cutaneous melanoma clinical trials.

Recruiting cutaneous melanoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cutaneous Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT

Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARING THE COMBINATION OF NAPORAFENIB + TRAMETINIB TO PHYSICIAN’S CHOICE OF THERAPY (DACARBAZINE, TEMOZOLOMIDE OR TRAMETINIB MONOTHERAPY) WITH A DOSE OPTIMIZATION LEAD-IN [SEACRAFT-2]

Czechia, Sweden, France, Spain, Belgium, Netherlands +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

Germany, France, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A phase 2 clinical trial on neoadjuvant pembrolizumab in patients diagnosed with high-risk melanoma without clinical evidence of metastatic dissemination.

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator’s choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine® IMA203-301)

Germany, France, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination with Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients with NRAS-Mutant Advanced Melanoma

Germany, Norway

Human Pharmacology (Phase I)- Other EU CTIS Study details

Cutaneous Melanoma trials by city

Cutaneous Melanoma in Toronto Cutaneous Melanoma in Vancouver Cutaneous Melanoma in Montreal Cutaneous Melanoma in Calgary Cutaneous Melanoma in Edmonton Cutaneous Melanoma in Ottawa Cutaneous Melanoma in Winnipeg Cutaneous Melanoma in Quebec City Cutaneous Melanoma in Hamilton Cutaneous Melanoma in Kitchener Cutaneous Melanoma in London Cutaneous Melanoma in Halifax Cutaneous Melanoma in New York Cutaneous Melanoma in Los Angeles Cutaneous Melanoma in Chicago Cutaneous Melanoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease